vision: 177lu-psma-617 in psma-positive mcrpc
Published 2 years ago • 95 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
40:03
psma & lutetium-177 in 2022 | eugene kwon, md | diy combat manual for beating prostate cancer part 4
-
6:22
prostate cancer treatment in germany - lutetium-177 psma | stories from our patients
-
12:58
targeted and systematic prostate biopsy
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
10:20
psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
1:09
psma imaging pre- and post-177lu-psma-617 treatment in mcrpc
-
1:38
177lu-psma i&t for patients with psma-positive mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
1:38
dr. sartor on outcomes with 177lu-psma-617 after radium-223 in mcrpc
-
3:41
177lu-psma-617 vs. cabazitaxel for mcrpc
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
3:25
highlights on lu-psma-617 in taxane-naive patients with mcrpc: the psmafore study
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms